Oral Communications. Session 2
Oral Communications

Speakers

Isabel Ramos

São João Hospital Center. Porto, Portugal.

Read More

Neurocognitive disorders in patients with HIV infection with virological suppression > 10 years

Elisabetta Teti, M.D., Ph.D.

Clinical Infectious Diseases, Tor Vergata University. Rome, Italy.

Read More

New Advanced EEG Technique (LORETA – Low Resolution Electromagnetic Tomography) to Early Detect and Monitor HIV Brain Damage

Guida Da Ponte, M.D., Ph.D.

Barreiro-Montijo Hospital Center. Portugal

Guida da Ponte, M.D., Ph.D., psychiatrist, Consultation-Liaison Psychiatry, Department of Psychiatry and Mental Health – Centro Hospitalar Barreiro-Montijo, Portugal. One of the major fields of practice is with HIV patients with a psychiatric outpatient clinic dedicated to this condition. Author of scientific publications, mainly in the areas of neurocognitive disorders, depression, anxiety and psychopharmacology and antiretroviral interactions.

Read More

What do psychiatrists need to know when treating HAND – Differential Diagnosis and HAART neurotoxicity

Jose A. Muñoz-Moreno, Ph.D.

Lluita contra les Infeccions Foundation, Germans Trias i Pujol University Hospital. Barcelona, Spain

Jose A. Muñoz-Moreno is a clinician and researcher at the Lluita contra les Infeccions Foundation, located in the Germans Trias i Pujol University Hospital, in Barcelona (Catalonia, Spain). He earned the Ph.D. degree in Neurosciences in 2012 (Cum Laude), and currently he is also a collaborating professor with the Universitat de Barcelona (UB) and the Universitat Autònoma de Barcelona (UAB).

Muñoz-Moreno is involved in projects that address psychology and the human behaviour associated with HIV infection. In terms of study, he mostly investigates the neurocognitive features of HIV infection, the impact of HIV and antiretroviral treatments on quality of life and emotional status, and adherence to antiretroviral therapy.

Muñoz-Moreno’s recent work particularly focuses on assessment methods to detect HIV-related neurocognitive changes and the current profile of neurocognitive impairment in people living with HIV infection.

Read More

Transdermal Rivastigmine for HIV-Associated Cognitive Impairment: Preliminary Results from a Randomized